Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States - Fasching, Peter; Huang, M.; Haiderali, A.; Xue, W.; Pan, W.; Zhou, Z-Y.; Hu, P.; Chaudhuri, M.; De Tilleghem, C. Le Bailly; Cappoen, N.; O'Shaughnessy, J. (ANNALS OF ONCOLOGY, 2022)
CRIS-Team WoS Importer:2022-06-03